Pharsight

Vizamyl patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7351401 GE HEALTHCARE Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition
Jan, 2023

(8 months ago)

US8236282 GE HEALTHCARE Benzothiazole derivative compounds, compositions and uses
May, 2024

(7 months from now)

US7270800 GE HEALTHCARE Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
Sep, 2025

(1 year, 10 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8691185 GE HEALTHCARE Benzothiazole derivative compounds, compositions and uses
Jan, 2023

(8 months ago)

US8916131 GE HEALTHCARE Radiopharmaceutical composition
Sep, 2028

(4 years from now)

Vizamyl is owned by Ge Healthcare.

Vizamyl contains Flutemetamol F-18.

Vizamyl has a total of 5 drug patents out of which 2 drug patents have expired.

Expired drug patents of Vizamyl are:

  • US8691185
  • US7351401

Vizamyl was authorised for market use on 25 October, 2013.

Vizamyl is available in injectable;intravenous dosage forms.

Vizamyl can be used as diagnostic radioimaging.

The generics of Vizamyl are possible to be released after 16 September, 2028.

Drugs and Companies using FLUTEMETAMOL F-18 ingredient

Market Authorisation Date: 25 October, 2013

Treatment: Diagnostic radioimaging

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage

VIZAMYL family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic